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Polycythemia vera (PV), essential thrombocythemia and
primary myeloﬁbrosis, are myeloproliferative neoplasms
(MPNs) with distinct clinical features and are associated with
the JAK2V617F mutation. To identify genomic anomalies
involved in the pathogenesis of these disorders, we proﬁled
87 MPN patients using Affymetrix 250K single-nucleotide
polymorphism (SNP) arrays. Aberrations affecting chr9 were
the most frequently observed and included 9pLOH (n¼16),
trisomy 9 (n¼6) and ampliﬁcations of 9p13.3–23.3 (n¼1),
9q33.1–34.13 (n¼1) and 9q34.13 (n¼6). Patients with trisomy
9 were associated with elevated JAK2V617F mutant allele
burden, suggesting that gain of chr9 represents an alternative
mechanism for increasing JAK2V617F dosage. Gene expres-
sion proﬁling of patients with and without chr9 abnormalities
(þ9, 9pLOH), identiﬁed genes potentially involved in disease
pathogenesis including JAK2, STAT5B and MAPK14. We also
observed recurrent gains of 1p36.31–36.33 (n¼6), 17q21.2–
q21.31 (n¼5) and 17q25.1–25.3 (n¼5) and deletions affecting
18p11.31–11.32 (n¼8). Combined SNP and gene expression
analysis identiﬁed aberrations affecting components of a non-
canonical PRC2 complex (EZH1, SUZ12 and JARID2) and genes
comprising a ‘HSC signature’ (MLLT3, SMARCA2 and PBX1).
We show that NFIB, which is ampliﬁed in 7/87 MPN patients and
upregulated in PV CD34þ cells, protects cells from apoptosis
induced by cytokine withdrawal.
Blood Cancer Journal (2011) 1, e40; doi:10.1038/bcj.2011.39;
published online 11 November 2011
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Introduction
The Ph-negative myeloproliferative neoplasms (MPNs) including
polycythemia vera (PV), essential thrombocythemia (ET) and
primary myeloﬁbrosis (PMF) are clonal hematopoietic disorders
characterized by the overproduction of blood cells belonging to
the myeloid, megakaryocytic and/or erythroid lineages.
1
Although clinically distinct, these diseases are characterized
by a recurrent mutation, JAK2V617F, which is present in B95%
of patients with PV, B65% with PMF and B55% with ET.
2 JAK2
is one member of the Janus family of non-receptor tyrosine
kinases that transduces signals downstream of type I and II
cytokine receptors via signal transducer and activators of
transcription (STATs), and is an important regulator of cell
survival, proliferation, differentiation and apoptosis.
3,4 The
JAK2V617F mutation leads to autophosphorylation of JAK2
and constitutive activation of downstream pathways including
the Janus kinase (JAK)/STAT, phosphatidylinositol 3 kinase/AKT
(v-akt murine thymoma viral oncogene homolog 1) and
mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase pathways.
5–9 Although overexpression of
JAK2V617F in a murine bone marrow transplant models leads
to a PV-like disease and megakaryocytic hyperplasia, such mice
do not develop thrombocytosis and questions regarding the
effect of allele dosage on disease phenotype remain unan-
swered. The ﬁnding of Theocharides et al.
10 that 70% of
JAK2V617F-positive MPN patients went on to develop
JAK2V617F-negative acute myeloid leukemia (AML), suggests
that additional predisposing factors may precede the JAK2
mutation. Recently, several acquired inactivating mutations in
TET2,
11 ASXL1
(ref. 12) and IDH1/2
(ref. 13) in MPN progenitors
were identiﬁed, and it is likely that additional genes are involved
in the initiation of a pre-leukemic clone or as disease modiﬁers,
in co-operation with JAK2V617F.
Previous studies using standard karyotyping revealed abnorm-
alities in 50% of PMF patients, 15% of PV and o5% of ET
patients.
14–16 Although such conventional chromosome analysis
has proven useful for diagnosis and prognostic information in
PMF patients and other myeloid malignancies, the sensitivity of
these approaches is limited. Indeed, studies by Tefferi using
comparative genomic hybridization (CGH) oligonucleotide
arrays to identify genomic aberrations in a panel of MPN
patients, detected copy number aberrations (CNAs) in 29% and
18% of patients with PV and ET, respectively, while cytoge-
netics for these patients appeared normal.
17 Recently, high-
resolution single-nucleotide polymorphism (SNP) arrays have
emerged as a powerful, high-throughput technology to allow
detection of micro-deletions and duplications and inference of
loss of heterozygosity (LOH) from genotype calls, in cases where
conventional cytogenetic technologies and array CGH are
unsuccessful. Since then, SNP arrays have been successfully
used to identify cryptic oncogenic deletions and duplications
affecting putative oncogenes and tumor suppressors in various
hematological malignancies. For example, the identiﬁcation of Received 16 June 2011; accepted 11 August 2011
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array analysis.
11,18 Similarly, PAX5 was identiﬁed as a target for
mutation in B-cell acute lymphocytic leukemia using SNP
arrays.
19 Recent studies using high-resolution SNP arrays
identiﬁed novel, recurrent aberrations in a large cohort of
MPN patients and revealed associations between speciﬁc
chromosomal anomalies and disease progression.
20
Here, we report an integrative analysis of chromosomal
abnormalities and gene expression changes in MPN patients.
We proﬁled CNAs in peripheral blood granulocytes of 87
patients with MPN and identify new regions affected by
recurrent chromosomal aberrations. In a subset of the proﬁled
patients, genomic copy number changes could be correlated
with gene expression in granulocytes, leading to the identiﬁca-
tion of novel genes deregulated in MPN. We show that patients
affected by chromosome 9 abnormalities, which represent the
most frequent CNA, are characterized by deregulation of set of
genes including JAK2, STAT5B and MAPK14, suggesting that
these genes may be involved in disease pathogenesis. We also
performed meta-analysis of ﬁve independent MPN expression
data sets to identify genes commonly deregulated in MPN.
Comparison of genes identiﬁed in these meta-analysis with
those affected by CNAs, revealed genes that may have important
roles in disease pathogenesis including EZH1, MLLT3, SOCS3
and SMARCA2. Finally, we show that the transcription factor
NFIB, which is located adjacent to JAK2 and upregulated in our
MPN meta-analysis, leads to increased net cell growth and
decreased apoptosis in the murine hematopoietic cell line,
Ba/F3-EPOR.
Patients and methods
Patient samples
A total of 87 MPN patients (32 PV, 24 PMF and 31 ET) were
included in this study (Supplementary Table S1). Samples were
obtained with informed consent at the Dana–Farber Cancer
Institute as described previously.
8
SNP arrays
DNA was extracted from peripheral blood granulocytes using
the QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA, USA)
and analyzed with GeneChip Mapping 250K arrays according to
the manufacturer’s protocol (Affymetrix, Santa Clara, CA,
USA).
11 Brieﬂy, 250ng of genomic DNA was digested by Nsp
restriction enzymes and ligated with the appropriate adaptor for
ampliﬁcation with Platinum Pfx DNA polymerase (Invitrogen,
Carlsbad, CA, USA). Three 100ml PCR reactions were carried
out for each adaptor-ligated DNA sample. PCR products were
pooled and puriﬁed. In all, 40mg of PCR product was
fragmented with DNase I and visualized on a 4% TBE agarose
gel. Fragmented PCR products were subsequently end-labeled
with biotin. Hybridization and washing was performed using the
Affymetrix Fluidics Station 450 and Gene chip and chips were
scanned on an Affymetrix GeneChip Scanner G7 (Affymetrix).
JAK2V617F allele burden analysis
The JAK2V617F allele status was assessed using a quantitative
reverse transcriptase-PCR assay as previously described.
21 In
brief, a standard curve for the proportion of JAK2V617F/total
JAK2 against the dCT (Ct-JAK2V617F-CtJAK2WT) was generated
using DNA from a healthy control and a PV erythroid colony
homozygous for the JAK2V617F mutation. This method was
then used to determine the JAK2V617F allele burden (%) in
DNA extracted from individual patient granulocytes.
Data analysis
CNA analysis. These data were processed and analyzed
using a custom developed procedure (Supplementary Figure S1).
Genotype calls were generated by GTYPE (Affymetrix) from CEL
ﬁles and 250K library ﬁles for Nsp arrays. Raw data were
normalized using invariant set normalization method. The
intensity value for each SNP was extracted using a model-based
perfect match/mismatch algorithm in dChip (http://biosun1.
harvard.edu/complab/dchip/). The log2 ratio of the intensity
for each SNP for each sample relative to data from 60
unrelated CEU subjects of HapMap project (http://www.
hapmap.org) was calculated. The circular binary segment
algorithm implemented in BioConductor DNAcopy package
(http://bioconductor.org) was applied to the log2 ratio data to
segment the chromosome into contiguous regions of equal copy
number based on a maximal t-statistics with the use of a
permutation reference distribution (using coordinates of the SNP
based on Genome Build HG-17).
22 Segmental value was
calculated by averaging copy number change values for the
SNPs residing in that segment. The baseline value of genome-
wide segments in the sample with a bias in regional changes (in
case of the samples with more regional gains than losses, or vice
versa or with only regional gains or losses) may be shifted
because of the preceding steps of global normalization and
median centering. To correct the baseline, the segmental values
were adjusted by subtracting the median of segmental change
values for all the SNPs. Considering a large segment with low-
level copy number change as important as a small segment with
high-level change, the adjusted segmental change value was
further weighted by multiplying log10 of the length of that
segment. A segment in the MPN sample was considered
signiﬁcant if its segmental value is 43 s.d. of segmental values
in a range of Q1 3*(Q2 Q1) to Q2þ3*(Q2 Q1) where Q1 or
Q2 are the 25% or 75% percentile of segmental values in all the
samples, respectively. The signiﬁcant segments having an
overlap of 475% with CNA regions in normal subjects reported
in the Database of Genomic Variations (http://projects.tcag.ca/
variation/) were ﬁltered out for further analysis. The frequencies
of copy number changes in either direction for signiﬁcant
segments among MPN samples were summarized for each
disease using the boundary information of signiﬁcant segments.
To assess the signiﬁcance of genomic aberrations in a group of
samples, the permutation was performed to assess the frequency
of genomic aberrations occurring in the genome by a random
chance. The genome and aberrant regions were fragmented into
50kb blocks and the fragmented blocks for each sample were
randomly assigned to any block in the genome. The frequency
of aberrations occurring in every block in the genome at random
was calculated and compared with the actual frequency of
aberrations. These steps were repeated 1000 times. If the
random chance of obtaining a proportion higher than actual
frequency of genomic aberrations for a given region is o5%
(equivalently to 50 times from 1000 permutations), the recurrent
aberration for a region was determined to be signiﬁcant. The
Fisher’s exact test was performed to examine whether a
particular chromosomal aberration was associated with JAK2
mutation status or disease type. To determine if the genomic
instability proﬁles were segregated by disease type, hierarchical
clustering of genome-wide copy number change proﬁles was
performed in PV, ET and PMF patients using the distance of
Pearson correlation co-efﬁciencies.
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MPN genotypes with 60 CEU unrelated normal controls derived
from the HapMap project (http://www.hapmap.org). A Hidden
Markov-based algorithm was used to infer LOH from unpaired
samples implemented dChip.
23 The regions with a minimum of
80% probability of LOH call were identiﬁed for each sample
and LOH regions for MPN and HapMap normal samples were
then summarized and compared.
RNA extraction and microarray
Total mRNA was extracted from peripheral blood granulocytes
of 38 selected MPN patients and 11 normal control patients
using Trizol (Invitrogen). In all, 10mg was hybridized to
HGU133A V2 arrays (Affymetrix). Data were analyzed using
Genespring 11.0.2 (Agilent Technologies Inc., Santa Clara, CA,
USA) following RMA normalization and genes with a fold
change of X1.5 (Po0.05) were considered statistically sig-
niﬁcant. For MPN meta-analysis, a one-sided t-test (Po0.05)
was performed between disease and control samples for data
sets 1, 2, 3 and 5 (PV data set 1: CD34þ cells from 10 PV and 9
normal controls,
24 PMF data set 2: CD34þ cells from 3 PMF
and 3 normal controls,
25 ET data set 3: platelets from 6 ET and 5
normal controls,
26 ET data set 4: CD34þ derived megakar-
yocyte cells from 2 ET and 2 normal controls,
27 MPN data set 5:
granulocytes from 93 MPN patients and 11 normal controls,
unpublished data, includes 38 MPN patients described above).
For data set 4, an average of log ratios of two samples (X2-fold)
was used due to limited sample size. Genes deregulated in the
same direction (average of X1.5-fold and present in at least 3/5
data sets) were considered signiﬁcant. For analysis of gene
expression between patients with chromosome 9 aberrations
and normal chromosome 9 cytogenetics, a one-sided t-test was
performed and genes with a fold change X1.5 (Po0.05) were
considered signiﬁcant.
Bioinformatic analysis
Gene biofunctions and network analysis was performed using
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City,
CA, USA).
Cell culture
293T cells were grown in Dulbecco’s modiﬁed Eagle’s medium
containing 10% (v/v) fetal bovine serum (FBS), 50U/ml
penicillin and 50mg/ml streptomycin. Ba/F3 cells expressing
the murine erythropoietin receptor (Ba/F3-EPOR) were pre-
viously described
28 and cultured in RPMI containing 10%
(v/v) FBS supplemented with recombinant erythropoietin hEPO
(1U/ml) (Cell Sciences, Canton, MA, USA). HEL cells were
grown in RPMI containing 10% (v/v) FBS. TF-1 cells were
cultured in RPMI containing 10% (v/v) FBS supplemented with
human granulocyte-macrophage colony-stimulating factor (2ng/ml)
(Peprotech, Rocky Hill, NJ, USA). UKE-1 cells (Gift of Gabi
Vohwinkel, University Hospital Eppendorf, Hamburg, Germany)
were grown in Iscove’s modiﬁcation of Dulbecco’s medium
containing 10% (v/v) FBS, 10% (v/v) horse serum and hydro-
cortisone (10
 6 M) (Sigma-Aldrich, St Louis, MO, USA). For JAK2
inhibition studies, HEL and UKE-1 cells were treated with
either JAK inhibitor I (Calbiochem, Gibbstown, NJ, USA) or
NVP-BSK805 Inhibitor (1–2mM) (Novartis, Schaumberg, IL,
USA), respectively, for 16h, using dimethylsulphoxide as a
control.
Viral constructs and transduction
Full-length human NFIB complementary DNA (cDNA) was
obtained from Open Biosystems (Huntsville, AL, USA) and
cloned into the two promoter EF1a-cytomegalovirus-green
ﬂuorescent protein (GFP) lentiviral vector (Gift of Dr Linzhao
Cheng, John Hopkins). Full-length human JAK2WT and
JAK2V617F cDNA was subcloned from the MSCV-Neo/Puro
retroviral vector
8 into the two promoter A2-GFP lentiviral
vector. Viral particles were produced by transient transfection
of 293T cells with pRSV-REV (Rous sarcoma virus-REV), pMDLg/
pRRE (gag/pol elements) and pMD.G (envelope elements)
plasmids with Fugene6:DNA (Roche, Mannheim, Germany).
After 24h, transfection reagent was removed and replaced with
RPMI and incubated at 321C for 48h. Supernatants were pooled
and ﬁltered through a 0.45mm syringe ﬁlter for immediate use.
For transduction of Ba/F3-EPOR or TF-1 cells, 2 10
6 cells were
pelleted and resuspended in 2ml of lentivirus with polybrene
(4mg/ml) and spinoculated at 1010 g for 2h at 251C. Infected
cells were then cultured for 48h and the percentage of GFP was
determined by ﬂow cytometry.
cDNA preparation and quantitative reverse
transcriptase- PCR
cDNA was synthesized from 1mg of total RNA using Iscript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Quantitative
reverse transcriptase-PCR reactions were performed using
Quantitect SYBR Green PCR Kit (Qiagen) using the Mx3000P
Real-Time PCR System (Stratagene, Agilent Technologies,
La Jolla, CA, USA). Quantitect primers (Qiagen) used for
quantitative quantitative reverse transcriptase-PCR are located
in Supplementary Table S2.
Cytokine withdrawal
Sorted GFPþ Ba/F3-EPOR cells were cultured in RPMI plus
erythropoeitin (EPO) (1U/ml) and cumulative cell growth counts
were performed over 10 days by Trypan blue exclusion. For EPO
withdrawal studies, cells were washed three times in phosphate-
buffered saline and seeded at 1 10
5 cells/ml with varying
concentrations of EPO (1, 0.1 and 0.01U/ml) for 2 days. The
percentage of dead cells was calculated by Trypan blue
exclusion.
Results
Identiﬁcation of novel MPN-associated disease genes
using a combination of SNP and gene expression
proﬁling
To identify genes recurrently affected by genomic aberrations in
MPN, we hybridized DNA from peripheral blood granulocytes
of 87 MPN patients (32 PV, 24 PMF and 31 ET) to Affymetrix
250K SNP arrays. Analysis of genomic proﬁles for CNAs and
copy neutral LOH/uniparental disomy conﬁrmed previously
reported chromosomal abnormalities in MPN, including recur-
rent gain of 1q (n¼4), trisomy 8 (n¼2), 9pLOH (n¼16),
trisomy 9 (n¼6) and deletions in 20q11.21–13.13 (n¼4)
20,29
(Figure 1a; Supplementary Table S1). We also found that several
genes mutated in MPN were also affected by genomic
aberrations in our cohort. For example, analysis of the TET2
gene, which is mutated in B12% of patients with MPN,
11
revealed small deletions at chr4q24 affecting TET2 in two PV
patients (Supplementary Figure S1). We also observed loss of
20q11.21–q13.12 in one PV (s328) and one PMF patient (s212),
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Figure 1 CNAs in MPN (a). Ideogram representing regions of chromosomal gains (red) and loss (green) identiﬁed using Affymetrix GeneChip
Mapping 250K arrays in 87 patients with MPN. Individual lines represent a single patient (b). Top: genomic proﬁle of chromosome 17 in one
patient (s531) showing a gain at 17q21.1–21.31 encompassing 144 genes including EZH1 and ITGA2B, which are also transcriptionally
upregulated in MPN patients (Supplementary Table S6). Bottom: genomic proﬁle of chromosome 6 in one patient (s242) showing a gain at 6p22.3
encompassing JAR1D2. Red lines represent the mean log2 ratio of the intensity of the samples relative to 60 unrelated HapMap normal controls.
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to be mutated in B11% of myelodysplastic syndromes (MDS)
and in B7% of patients with MPN ET and PMF,
30 gain of
ch11q23.3 encompassing CBL in one ET patient (s403) and loss
of chr7q35 harboring EZH2 in one PMF patient (s212)
(Supplementary Table S1).
Overall, our analysis identiﬁed CNAs in 88% of MPN
patients, (77/87), however, the majority (B90%) of recurrent
aberrations occurred at a frequency of o5%. The most frequent
abnormalities involved chromosome 9, including 9pLOH
(n¼16) as well as gains of whole chromosome 9 (n¼6) and
partial ampliﬁcations including 9p13.3–23.3 (n¼1), 9q33.1–
34.13 (n¼1) and 9q34.13 (n¼6). Recurrent gains of 1p36.31–
36.33 (n¼6), 17q21.2–q21.31 (n¼5), 17q25.1–25.3 (n¼5)
and deletions of 18p11.31–11.32 (n¼8) and 15q15.3 (n¼7)
were also observed (Table 1). In addition to these larger
aberrations, a subset of CNAs identiﬁed in our screen involved
smaller regions of recurrent gain or loss, typically containing
o10 genes. We hypothesized that these areas may contain
putative oncogenes or tumor suppressors, as in the case of the
TET2 tumor suppressor. Such candidates include FLI1 and ETS1,
located in a 754–841-kb region of loss (3/87), TCBA1 located in
a 600-bp region of loss (3/87) and CNTNAP2 located in a 35-kb
region of loss (2/87) (Supplementary Table S1).
In order to further investigate the disease potential of these
genomic gains and losses, we compared genes affected by CNAs
in our MPN cohort (X2 patients; 4448 genes) (Supplementary
Table S3) with genes deregulated in peripheral blood granulocytes
from a subset of these patients (n¼37, 10 PV, 17 ET and
10 PMF, Supplementary Table S1) compared with normal
controls (n¼11) (X1.5-fold, Po0.05; 1447 genes, Supplemen-
tary Table S4) and cancer-associated genes obtained from the
Catalogue of Somatic Mutations in Cancer (COSMIC) (426
genes) (Supplementary Figure S2). Of the 426 COSMIC genes,
75 were affected by CNAs and 42 were deregulated in
expression (Supplementary Table S5). Nine genes fulﬁlled all
criteria and these included JAK2 and Translocated Promoter
Region, which were both affected by copy number gains and
overexpressed in MPN patients compared with normal controls.
Using this tri-level analysis, we identiﬁed aberrations affecting
components of a non-canonical PRC2 complex including
upregulation of SUZ12 (1.8-fold, Po0.05), ampliﬁcation
and upregulation of EZH1 (5/87; 1.6-fold, Po0.05) and
ampliﬁcation of JARID2 (2/87) (Figure 1b). Several genes
constituting part of a HSC ‘gene signature’
31 were also identiﬁed
in our analysis, including MLLT3 and SMARCA2, ampliﬁed as a
result of trisomy 9 in six patients and PBX1 ampliﬁed in
three patients on chr1q22–1q25.3, strengthening the hypothesis
Table 1 SNP arrays identify regions of recurrent gain or loss in MPN patients
Chr Ab Start End Dist
(kb)
Freq COSMIC database MPN vs control
(41.5-fold, Po0.05)
MPN meta-analysis
(41.5-fold, Po0.05)
1 Gain 1p36.33 1p36.31 4338 6/87 PRDM16 LRRC47 F
1 Gain 1q32.1 1q44 45208 4/87 ELK4, MDM4,
SLC45A3
ADSS, ANGEL2, ARF1, ARID4B,
BTG2, CNIH4, FAIM3, FBXO28,
HEATR1, LGALS8, NUAK2, PFKFB2,
RAB3GAP2, RCOR3, TOMM20,
TRAF3IP3, TSNAX, ZC3H11A
AKT3, GALNT2, LGALS8,
MTR, PSEN2, RAB3GAP2,
RPS6KC1, SMYD2
8 Gain 8p23.1 8p23.1 428 4/87 FF F
9 Gain 9p24.3 9p23 10489 6/87* JAK2 JAK2, SMARCA2 JAK2, SMARCA2
9 Gain 9p23 9p13.3 16366 7/87* CDKN2A, MLLT3,
NFIB
F ADFP, MLLT3, NFIB
9 Gain 9p13.3 9q33.1 83625 6/87* FANCC, FANCG, GNAQ,
NR4A3, OMD, PAX5,
PTCH, SYK, TAL2 XPA
AGTPBP1, ANXA1, CTNNAL1,
DCTN3, DDX58 KLF4, NDUFB6,
NOL8 NR4A3, SMU1, SPTLC1 T
DRD7, TLN1
ABCA1, CDC14B, DAPK1
DDX58, KIAA0367, NTRK2,
TMOD1, TPM2, TXNDC4
9 Gain 9q33.1 9q34.13 10771 7/87* CEP1 CDK5RAP2, FBXW2, GAPVD1,
GOLGA1, PBX3 POLE3, PRPF4,
PTGS1, RABGAP1, STOM
PTGS1, RABGAP1
9 Gain 9q34.13 9q34.13 1097 10/87* FF ANGPTL2
9 Gain 9q34.13 11137 12/87* ABL1, BRD3, FNBP1,
NOTCH1, NUP214,
SETTSC1
ASB6, CDK9, GPR107, LCN2,
RALGDS SET, SPTAN1, SSNA1
F
12 Gain 12p13.33 12p13.33 1008 4/87 FF F
15 Loss 15q15.3 15q15.3 172 7/87 FF F
17 Gain 17q21.2 17q21.31 3984 5/87 BRCA1, ETV4 ATP6V0A1, EZH1, FMNL1 HEXIM1,
ITGA2B, MAP3K14, PSME3
EZH1, ITGA2B
17 Gain 17q25.1 17q25.3 9770 5/87 ASPSCR1, CANT1 GGA3, MAFG, SEC14L1, SGSH,
SLC16A3 ST6GALNAC2,WBP2
BAIAP2, EXOC7,
SEC14L1 SOCS3
18 Loss 18p11.32 18p11.31 813 8/87 FF F
20 Loss 20q11.23 20q13.12 9917 4/87 MAFB, TOP1 BLCAP, BPI, CTNNBL1,
MMP9, SFRS6
C20orf67, EYA2, HNF4A
L3MBTL, SRC,
TGM2, UBE2C
20 Gain 20q13.33 20q13.33 3353 4/87 SS18L1 LIME1, PCMTD2, RPS21 DATF1
Abbreviations: CNA, copy number aberration; COSMIC, Catalogue of Somatic Mutations in Cancer; ET, essential thrombocythemia; MPN,
myeloproliferative neoplasm; PMF, primary myeloﬁbrosis; PV, polycythemia vera; SNP, single-nucleotide polymorphism.
Frequently occurring CNAs identiﬁed using 250K SNPArray Analysis in MPN patients (n¼87). Asterisks indicate that these frequencies include six
cases of whole chromosome 9 gain. Genes affected by CNA, somatic mutations in cancer (COSMIC) and gene expression analysis (MPN vs
normal; genes deregulated in peripheral blood granulocytes from 37/87 MPN patients (10 PV, 17 ET and 10 PMF) compared with 11 normal
controls (X1.5-fold, Po0.05; Supplementary Table S4) and meta-analysis of ﬁve MPN array data sets (one-sided t-test, Po0.05, average of
1.5-fold in 3/5 data sets; Supplementary Table S6) are shown in the far right columns.
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progenitor (Table 1).
Finally, we compared genes affected by CNAs with those
deregulated in a comprehensive MPN meta-analysis. Analysis of
ﬁve individual MPN data sets comparing patient and normal
control samples identiﬁed 574 upregulated genes and 636
downregulated genes. Comparison of this data set with genes
affected by genomic aberrations in our MPN patient cohort
(CNAs present in X2 patients), identiﬁed 81 upregulated genes in
regions of chromosome gain and 20 downregulated genes in
regions of loss (Supplementary Table S6). Ingenuity pathway
analysis of these genes revealed an enrichment of genes
belonging to various signaling pathways including the JAK/STAT,
interleukin-8 and erythropoietin pathways, reinforcing the role of
dysregulated JAK/STAT signaling in MPN (Table 2). Furthermore,
genes previously implicated in hematological disease such as
PBX1, PDE4C, PTGS1 and SRC as well as in cell growth and
proliferation and apoptosis were also enriched (Table 3). Taken
together, these data indicate that genomic aberrations present in
MPN account for a proportion of gene expression changes, which
may have a role in disease pathogenesis.
Aberrations involving chromosome 9 are associated
with dysregulated gene expression
Previous studies show that wild-type JAK2 can exert a dominant-
negative effect over mutant JAK2V617F, suggesting that there
may be a selective advantage for elevating the ratio of
JAK2V617F/JAK2WT.
32 We observed that the majority of patients
with a high JAK2V617F allele burden (485% JAK2V617F) exhibit
chr9pLOH (86%; 12/14), conﬁrming previous studies that
JAK2V617F mutant allele status can be increased through LOH
because of mitotic recombination
8 (Supplementary Table S1). We
also found that the majority of patients with trisomy 9 had an
elevated JAK2V617F allele burden (average 67%), consistent with
duplication of the mutant allele.
As trisomy 9 and 9pLOH represent the predominant CNAs in
MPN, we used gene expression proﬁling to investigate the
differences between patients with normal (n¼25) versus
abnormal chromosome 9 cytogenetics (n¼13). We identiﬁed
a set of 493 genes, including 210 upregulated and 283
downregulated genes that were differentially expressed between
these two groups (X1.5-fold, Po0.05) (Supplementary Table S7).
Among those genes upregulated in patients with chromosome 9
aberrations, were JAK2, STAT5B, MAPK14 and CD177 (Figure 2).
Table 2 MPN-associated pathways
Pathway P-value Genes Aberration Fold change
JAK/STAT signaling 3.4 10
 4 AKT3 Gain (3/87) 1.8
JAK2 Gain (6/87) 1.9
SOCS3 Gain (6/87) 1.9
JAK3 Gain (2/87) 1.5
IL-8 signaling 4.4 10
 4 AKT3 Gain (3/87) 1.8
ANGPT1 Gain (2/87) 2.8
AZU1 Gain (3/87) 1.5
IKBKB Gain (2/87) 1.6
PTK2B Gain (2/87) 1.8
SRC Loss (4/87)  1.6
Erythropoietin
signaling
5.5 10
 4 AKT3 Gain (3/87) 1.8
JAK2 Gain (6/87) 1.9
SOCS3 Gain (6/87) 1.9
SRC Loss (4/87)  1.6
Abbreviations: IL, interleukin; JAK, Janus kinase; MPN, myeloproli-
ferative neoplasm; SNP, single-nucleotide polymorphism; SOCS,
suppressor of cytokine signaling; STAT, signal transducer and
activators of transcription.
Ingenuity pathway analysis was performed using genes commonly
identiﬁed by SNP array (n¼87) and MPN meta-analysis (n¼114)
(89 genes).
Table 3 MPN-associated bio-functions
Functions P-value Genes Aberration Fold
change
Hematological disease (4.7 10
 5–1.2 10
 2)
Erythrocytosis 7.6 10
 4 JAK2 Gain (6/87) 1.9
SOCS3 Gain (6/87) 1.9
SRC Loss (4/87)  1.6
Leukemia 1.7 10
 3 AKT3 Gain (3/87) 1.8
JAK2 Gain (6/87) 1.9
JAK3 Gain (2/87) 1.5
MTR Gain (3/87) 1.9
PBX1 Gain (3/87) 1.7
PDE4C Gain (2/87) 2.7
PTGS1 Gain (7/87) 2.1
SRC Loss (4/87)  1.6
Cell growth and proliferation (1.5 10
 5–1.2 10
 2)
Colony
formation
9.2 10
 4 IFI16 Gain (3/87) 1.7
UBE2C Loss (3/87)  1.9
CLU Gain (2/87) 2.0
ELF3 Gain (3/87) 1.6
JAK2 Gain (6/87) 1.9
LAPTM4B Gain (2/87) 2.0
PDLIM2 Gain (2/87) 2.8
SRC Gain (4/87)  1.6
Proliferation
of cells
1.3 10
 3 AKT3 Gain (3/87) 1.8
ANGPT1 Gain (2/87) 2.8
BLZF1 Gain (3/87) 1.6
CD244 Gain (3/87) 2.2
HRPT2 Gain (3/87) 2.2
CLU Gain (2/87) 2.0
CTSB Gain (2.87) 2.7
ELF3 Gain (3/87) 1.6
ENPP2 Gain (2/87) 1.5
HNF4A Loss (3/87)  1.8
HPGD Gain (2/87) 2
IFI16 Gain (3/87) 1.7
IKBKB Gain (2/87) 1.6
ITGA2B Gain (5/87) 2.3
JAK2 Gain (6/87) 1.9
JAK3 Gain (2/87) 1.5
MAPRE Loss (2/87)  1.5
NFIB Gain (7/87) 2.3
PBX1 Gain (3/87) 1.7
SMARCA2 Gain (6/87) 2
SOCS3 Gain (6/87) 1.9
SRC Loss (4/87)  1.6
TGM2 Loss (4/87)  3.3
UBE2C Loss (3/87)  1.9
Cell death (2.5 10
 6–1.3 10
 2)
Apoptosis 3.2 10
 4 ANGPT1 Gain (2/87) 2.8
CLU Gain (2/87) 2.0
DAPK1 Gain (6/87) 1.8
DNAJB9 Loss (2/87) –1.6
IKBKB Gain (2/87) 1.6
PTK2B Gain (2/87) 1.8
SOCS3 Gain (5/87) 1.9
Abbreviations: IL, interleukin; JAK, Janus kinase; MPN, myeloproli-
ferative neoplasm; SNP, single-nucleotide polymorphism; SOCS,
suppressor of cytokine signaling.
Ingenuity pathway analysis was performed using genes commonly
identiﬁed by SNP array analysis (n¼87) and meta-analysis (n¼114)
(89 genes).
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chromosomal aberrations compared with PV
Although PV, ET and PMF patients may all harbor the
JAK2V617F allele, their clinical manifestations differ. This may
be at least in part explained by the gene dosage hypothesis,
which is based on the observation that homozygous JAK2V617F
mutant erythroid colonies are found in the majority of patients
with PV but rarely in ET patients.
33 This suggests that higher
kinase activity (JAK2V617F homozygosity) gives rise to an
erythroid/PV phenotype, whereas lower kinase activity
(JAK2V617F heterozygosity) leads to an ET phenotype. In
support of this model, we observed that JAK2V617F homo-
zygosity was associated with PV (64%; 9/14) and PMF (36%;
5/14) but not ET patients (Supplementary Table S1).
In addition to the role of JAK2V617F allele dosage, we
hypothesized that speciﬁc genomic aberrations may have a
role in disease phenotype. To test this, we performed
unsupervised hierarchical clustering of SNP proﬁles for
MPN patients heterozygous (allele burden range 1–85%) for
the JAK2V617F allele (n¼63) (Supplementary Figure S3).
Although genomic instability proﬁles of these MPN samples
did not segregate according to disease subtype, we found that
PMF patients were more likely to have large (410Mb)
chromosomal aberrations compared with ET or PV patients
(P¼0.009) (Figure 3). In addition, ET and PMF patients had
more moderate sized (1–10Mb) chromosomal aberrations than
PV patients (P¼0.01).
NFIB overexpression is associated with chromosome 9
ampliﬁcation and protects hematopoietic cells from
cytokine withdrawal-induced apoptosis
Accumulating evidence suggests that additional genetic lesions
cooperate with JAK2V617F to induce MPN. We identiﬁed NFIB
as a gene upregulated in our MPN meta-analysis, which
includes a recently published data set of CD34þ cells of PV
patients compared with normal CD34þ specimens.
24 In our
SNP array study, we show that NFIB, which lies 9.1MB
centromeric to the JAK2 locus, is ampliﬁed as a result of trisomy
9 in 6/87 MPN patients and gain of 9p23–13.3 in 1/87 MPN
patients. NFIB expression was not signiﬁcantly changed follow-
ing JAK2 inhibition in HEL cells and modestly upregulated
following JAK2 inhibition in UKE-1 cells, which are both
homozygous for the JAK2V617F mutant allele. NFIB expression
was not altered by overexpression of either WT or mutant JAK2
in TF-1 cells, which express wild-type JAK2 (Supplementary
Figure S4). In contrast, PIM1 was modulated in response to JAK2
inhibition or overexpression in keeping with its positive
regulation by JAK/STAT signaling. Taken together, these data
Chr9+ 9pLOH Chr9 normal
-3 3 0
Figure 2 Chromosome 9 aberrations are associated with elevated JAK2V617F allele burden and gene expression signature. Gene expression
differences in patients with normal (n¼25) versus abnormal (þ9, 9pLOH) chromosome 9 cytogenetics (n¼13) (Supplementary Table S7). A
subset of genes upregulated (42.7-fold, Po0.05; 26 genes) or downregulated (43-fold, Po0.05; 26 genes) in patients with chromosome 9
anomalies compared with normal chromosome 9 cytogenetics are displayed in a heatmap.
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upregulation of NFIB in MPN.
To explore the putative oncogenic potential of NFIB,w e
utilized the erythropoietin-dependent Ba/F3-EPOR murine
hematopoietic cell line. Stable overexpression of NFIB in
Ba/F3-EPOR cells protected cells apoptosis induced by EPO
withdrawal (Figure 4a) Furthermore, NFIB-infected Ba/F3-EPOR
cells displayed a modest, but consistent increase in cell
number compared with vector (Po0.02, Figure 4b). Taken
together, these data suggest that ectopic NFIB expression may
cooperate with aberrant JAK2 signaling to dysregulate normal
hematopoiesis.
Discussion
The recent use of genome-wide methods to interrogate copy
number alterations and gene expression changes in hematologic
malignancies has been critical to our understanding of the
mechanisms underlying these heterogeneous diseases. In this
study, we employed a combination of high-density SNP arrays
and gene expression arrays to identify novel oncogenic lesions
and dysregulated pathways in a cohort of 87 MPN patients. In
addition to identifying copy number variations affecting genes
TET2, ASXL1, EZH2 and CBL, which have previously been
reported in MPN,
34 we identiﬁed new MPN-associated aberra-
tions, which may have a role in disease initiation and/or
progression.
The most frequent aberrations observed in our patient cohort
involved gains of whole chromosome 9 or 9pLOH, suggesting
that genes on this chromosome may provide a selective clonal
advantage. Previous studies have shown that wild-type JAK2 is
capable of inhibiting STAT5 activation induced by mutant
JAK2V617F.
6 This inhibition is presumably due to competition
between the two JAK2 forms for cytokine receptor binding
because wild-type JAK2 does not affect autophosphorylation
of JAK2V617F.
8 Since JAK2 is present on chromosome 9,
we hypothesized that gain of chromosome 9 may provide
an alternative mechanism for cells to acquire an extra copy of
mutant JAK2. In support of this, we observed that a majority
of patients trisomy 9 were associated with high JAK2V617F
allele burden, suggesting that JAK2 was mutated in this
extra chromosome 9. Although the presence of other
disease-associated genes on chromosome 9 may also
contribute to the pathogenesis of MPN, these data support the
hypothesis that acquisition of an additional JAK2V617F mutant
allele, either by 9pLOH or trisomy 9, confers a selective,
competitive edge.
The ﬁnding that JAK2 and STAT5B are signiﬁcantly upregu-
lated in patients with trisomy 9 and 9pLOH, which are
comprised largely of PV patients (57%), reinforces the role of
aberrant JAK/STAT signaling in this disease subtype. MAPK14
(also known as p38a), which is also upregulated in patients with
chromosome 9 abnormalities, is a kinase that lies downstream of
JAK2, and is activated in response to pro-inﬂammatory stimuli
and hematopoietic growth factors. Recent studies reveal a role
PV PMF ET P value
Whole Chromosomal
Aberrations/person 0.2 0.2 0.04 0.4
Regions (>10Mb)/person 0.5 2.1 0.8 0.009
Regions (1-10Mb)/person 0.6 1.8 2.0 0.01
Regions (<1Mb)/person 2.4 3.5 3.8 0.4
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Figure 3 PMF and ET patients display higher frequencies of chromosomal aberrations compared with PV. Frequency plots of chromosomal gains
(red) or loss (green) in individuals with PV (n¼23), PMF (n¼15) and ET (n¼25). Y axis represents the frequency of copy number change in each
patient subgroup. T-test was used to identify signiﬁcant differences in the frequency of chromosomal aberrations between these three patient
subtypes.
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MAPK14 are anemic due to failed deﬁnitive erythropoiesis.
35
Given the association of high-level JAK2V617F expression with
a PV-like phenotype in murine models of MPN,
36 it is tempting
to speculate that aberrant expression of MAPK14 in patients with
two copies of JAK2V617F may activate an erythroid differentia-
tion pathway, contributing to the development of PV.
In addition to gaining extra copies of JAK2V617F, modulation
of JAK2 kinase activity may also have a role in disease
progression. The suppressor of cytokine signaling (SOCS)
proteins are negative regulators of cytokine signaling and are
expressed after cytokine stimulation, directly interacting with
JAK/STAT pathway members to modulate the responsiveness of
cells to further signaling.
37 Although it is postulated that SOCS
proteins are tumor suppressors, there is also evidence to suggest
that overexpression of SOCS may favor tumor progression.
Persistent expression of SOCS3 is observed in AML and
coincides with constitutive activation of JAK-STAT pathways.
38
Interestingly, our study identiﬁed SOCS3 within a region of
chromosomal gain on chromosome 17 in 6/87 patients and
SOCS3 was also upregulated B2-fold in our meta-analysis.
Although SOCS3 is a potent negative regulator of erythropoietin
signaling through the EPO receptor and wild-type JAK2, a study
by Hookham et al.,
39 revealed that SOCS3 is unable to
negatively regulate mutant JAK2V617F and in contrast,
enhanced the proliferation of Ba/F3 cells in the presence of
EPOR. Furthermore, SOCS3 degradation was inhibited by
JAK2V617F and this correlated with SOCS3 tyrosine phosphor-
ylation, a feature also observed in the PBMC of patients
homozygous for JAK2V617F. Indeed, we found that all patients
harboring a gain of chromosome 17q leading to ampliﬁcation of
SOCS3, had intermediate JAK2V617F allele burden (average
55.4%), supporting a model in which overexpression of SOCS3
may cooperate with JAK2V617F to enhance myeloproliferation.
Although aberrant JAK2 signaling is clearly a recurrent theme
in MPN, it is likely that other JAK2V617F-independent events
contribute to disease pathogenesis. Recent studies have identi-
ﬁed several disease-associated mutations such as TET2 and
ASXL1 that may initiate a premalignant clone, since they appear
to precede the JAK2V617F mutation.
2,11 In this study, we show
that NFIB, which we previously reported to be overexpressed in
CD34þ cells from nine PV patients compared with normal
controls, is ampliﬁed in six patients via gains of whole
chromosome 9 and in one patient by gain of region
9p23–13.3. Previous studies reporting overexpression of NFIB
in a small subset of PV patients (two with 9pLOH and two
without), hypothesized that this was a consequence of
9pLOH.
40 It was later shown, however, that NFIB was
overexpressed in eight MPN patients positive for endogenous
erythroid colony formation, however, none of these patients had
9pLOH.
41 Although the ectopic NFIB expression may be a
consequence of trisomy 9, it is also possible that NFIB may be
upregulated by other factors at the level of gene transcription.
Indeed, we observed that only two genes present in the 9pLOH
region, JAK2 and C9orf46, which encodes a transmembrane
protein with unknown function, were upregulated in these
patients compared with patients with normal chromosome 9
cytogenetics. NFIB encodes a CAAT box-binding transcription
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Figure 4 NFIB protects cells from cytokine withdrawal-induced cell death and promotes cell growth (a). Baf3/EPOR cells transduced with control
(EF) or EF-NFIB lentivirus for 48h and GFPþ cells were replated in RPMI with 1U/ml, 0.1U/ml and 0.01U/ml EPO for 48h. Cell viability was
determined by Trypan blue exclusion (b). Cumulative cell counts were performed over 10 days. Data are expressed as the average of three
independent experiments±s.e.m. (**Po0.05).
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cells increases resistance to TGF-b1 inhibition.
40 NFIB expres-
sion was not positively regulated by JAK2 in cell lines, however,
overexpression in Ba/F3-EPOR cells conferred a modest growth
advantage, and impaired apoptosis induced by EPO withdrawal.
The role of the related NFIA gene in erythropoiesis is well
established, and a recent study revealed structural alterations in
NFIA in 2% of chronic myeloid diseases, theoretically leading to
inactivation of the protein.
42 The functional role of NFIB in
normal and malignant hematopoiesis remains unknown. Pre-
liminary experiments suggest that NFIB is expressed at low
levels in human CD34þ cells, however, expression is
upregulated during normal megakaryocte differentiation (data
not shown). Future studies will seek to understand the effect of
NFIB overexpression on normal hematopoiesis and in the
context of the JAK2V617F overexpression.
In addition to NFIB, overlap of genes identiﬁed by our SNP
array and MPN meta-analysis identiﬁed several other potentially
interesting disease candidates. For example, MLLT3 and
SMARCA2, both of which are located on chromosome 9 and
upregulated in MPN patients, were identiﬁed as part of a gene
set expressed by ‘normal’ quiescent HSCs.
31 MLLT3 is a positive
regulator of erythroid and megakaryocyte differentiation during
normal hematopoiesis
43 and is also implicated in leukemo-
genesis, as a translocation fusion partner of MLL in AML.
44
EZH1, which is located in a region of chromosome gain
(17q21.1–21.31) in 5/87 patients and is upregulated in the MPN
meta-analysis, is an H3K27 methyltransferase that forms
part of a non-canonical PRC2 complex and has a role in
preserving H3K27me3, preventing derepression of PRC2 targets
involved in ESC pluripotency.
45 Recent studies identiﬁed loss of
function mutations in EZH2 in MDS and MPN, suggesting a
tumor-suppressor activity. Although the functional conse-
quences of EZH1 overexpression in MPN remains to be
elucidated, these studies highlight an emerging theme in
myeloid malignancies involving the dysregulation of genes
involved in epigenetic regulation, such as ASXL1, UTX, SETD2,
JARID1C and TET2.
Recent studies have demonstrated that JAK2V617F may affect
genomic stability by displacing HP1a from chromatin
46 and by
deregulating DNA double-strand break repair mechanisms.
47
Plo et al.,
47 showed that overexpression of JAK2V617F and to a
lesser extent wild-type JAK2 in Ba/F3-EPOR cells, led to an
increase in spontaneous homologous recombination and
RAD51 nuclear foci formation. JAK2V617F expression was
associated with genetic instability, as assessed by the higher
occurrence of centrosome abnormalities and sister chromatid
exchange. Furthermore, increased homologous recombination
and RAD51 formation was observed in patient CD34þ cells
from JAK2V617F-positive PV and PMF patients.
47 In support of
these studies, we observed signiﬁcantly more genomic aberra-
tions in patients with intermediate JAK2V617F allele burden
(1–85%) compared with patients with wild-type JAK2 (o1%
JAK2V617F) (data not shown). Unexpectedly, however, patients
with high JAK2V617F allele burden (485%) displayed fewer
aberrations. The ability of mutant JAK2 to induce hyper-
recombination is thought to facilitate mitotic recombination
that may lead to LOH and account for disease heterogeneity.
47
Whether genomic instability induced by JAK2V617F facilitates
leukemic transformation, however, remains contentious. For
example, in a study of 17 patients with JAK2V617F-positive
MPN that later transformed to AML, 9 patients went on to
develop JAK2V617F-negative AML.
10 Furthermore, a recent
study by Thoenssin et al.,
48 found no signiﬁcant association
between JAK2V617F mutation status and time to leukemic
transformation in patients with MPN-blast phase, suggesting the
existence of a pre-JAK2V617F clone.
Although unsupervised clustering of PV, ET and PMF patients
did not reveal distinct aberration patterns associated with these
MPN subtypes, we noted that PMF patients displayed more
chromosomal aberrations that PV or ET patients. These
observations are consistent with other studies showing that
patients with PMF exhibit increased copy number changes and
abnormal cytogenetics compared with PV or ET.
17 The
consequences of this increased genomic instability remains
unclear, however, a recent study investigating the chromosomal
abnormalities of patients with leukemic transformation of MPN,
revealed that time from diagnosis to leukemic transformation
was shorter for PMF than ET or PV patients.
48 Further analysis on
a larger cohort may help us determine the aberrations associated
with a speciﬁc MPN subtype.
In conclusion, we have used a combination of high-resolution
SNP arrays and gene expression arrays to identify novel
potential disease candidates that may have a role in MPN.
Future studies will seek to address the speciﬁc contribution of
aberrated genes and signaling pathways identiﬁed in this study
to the development of MPN.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
We thank David Ronald, director of Genotyping Facility at Albert
Einstein College of Medicine, and Greg Khitrov, director of Life
Science Technology Laboratory of Department of Medicine at
Mount Sinai School of Medicine for carrying out Affymetrix SNP
array experiments. We also thank Dr Weiguo Zhang (Duke U).
Supported by NIH Grant: R01 HL082950.
References
1 Delhommeau F, Jeziorowska D, Marzac C, Casadevall N.
Molecular aspects of myeloproliferative neoplasms. Int J Hematol
2010; 91: 165–173.
2 Tefferi A. Novel mutations and their functional and clinical
relevance in myeloproliferative neoplasms: JAK2, MPL, TET2,
ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128–1138.
3 Ihle JN, Gilliland DG. Jak2: normal function and role in
hematopoietic disorders. Curr Opin Genet Dev 2007; 17: 8–14.
4 Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine
receptors. Curr Opin Immunol 1998; 10: 271–278.
5 Morgan KJ, Gilliland DG. A role for JAK2 mutations in
myeloproliferative diseases. Annu Rev Med 2008; 59: 213–222.
6 James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C
et al. A unique clonal JAK2 mutation leading to constitutive
signalling causes polycythaemia vera. Nature 2005; 434:
1144–1148.
7 Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A et al.
Altered gene expression in myeloproliferative disorders correlates
with activation of signaling by the V617F mutation of Jak2. Blood
2005; 106: 3374–3376.
8 Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ
et al. Activating mutation in the tyrosine kinase JAK2 in
polycythemia vera, essential thrombocythemia, and myeloid
metaplasia with myeloﬁbrosis. Cancer Cell 2005; 7: 387–397.
9 Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identiﬁcation of an
acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;
280: 22788–22792.
10 Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS,
Lippert E et al. Leukemic blasts in transformed JAK2-V617F-
Identiﬁcation of novel lesions and pathways in MPN
KL Rice et al
10
Blood Cancer Journalpositive myeloproliferative disorders are frequently negative for the
JAK2-V617F mutation. Blood 2007; 110: 375–379.
11 Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S,
Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med
2009; 360: 2289–2301.
12 Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N,
Carbuccia N et al. Mutations of polycomb-associated gene ASXL1
in myelodysplastic syndromes and chronic myelomonocytic
leukaemia. Br J Haematol 2009; 145: 788–800.
13 Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the
leukemic transformation of myeloproliferative neoplasms. N Engl J
Med 2010; 362: 369–370.
14 Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW.
Cytogenetic ﬁndings and their clinical relevance in myeloﬁbrosis
with myeloid metaplasia. Br J Haematol 2001; 113: 763–771.
15 Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects
of essential thrombocythemia. Acta Haematol 2002; 108: 55–65.
16 Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A
et al. Cytogenetic studies at diagnosis in polycythemia vera:
clinical and JAK2V617F allele burden correlates. Eur J Haematol
2008; 80: 197–200.
17 Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J et al.
Oligonucleotide array CGH studies in myeloproliferative neo-
plasms: comparison with JAK2V617F mutational status and
conventional chromosome analysis. Leuk Res 2009; 33: 662–664.
18 Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG,
Massop M et al. Acquired mutations in TET2 are common in
myelodysplastic syndromes. Nat Genet 2009; 41: 838–842.
19 Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E,
Dalton JD et al. Genome-wide analysis of genetic alterations in
acute lymphoblastic leukaemia. Nature 2007; 446: 758–764.
20 Klampﬂ T, Harutyunyan A, Berg T, Gisslinger B, Schalling M,
Bagienski K et al. Genome integrity of myeloproliferative
neoplasms in chronic phase and during disease progression. Blood
2011; 118: 167–176.
21 Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P
et al. X-inactivation-based clonality analysis and quantitative
JAK2V617F assessment reveal a strong association between
clonality and JAK2V617F in PV but not ET/MMM, and identiﬁes
a subset of JAK2V617F-negative ET and MMM patients with clonal
hematopoiesis. Blood 2006; 107: 4139–4141.
22 Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary
segmentation for the analysis of array-based DNA copy number
data. Biostatistics 2004; 5: 557–572.
23 Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA et al.
Inferring loss-of-heterozygosity from unpaired tumors using high-
density oligonucleotide SNP arrays. PLoS Comput Biol 2006; 2:e 4 1 .
24 Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S, Najfeld V,
Min DJ et al. Transcriptional proﬁling of polycythemia vera
identiﬁes gene expression patterns both dependent and indepen-
dent from the action of JAK2V617F. Clin Cancer Res 2010; 16:
4339–4352.
25 Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E
et al. Molecular proﬁling of CD34+ cells in idiopathic myelo-
ﬁbrosis identiﬁes a set of disease-associated genes and reveals the
clinical signiﬁcance of Wilms’ tumor gene 1 (WT1). Stem Cells
2007; 25: 165–173.
26 Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL,
Bahou WF. Platelets express steroidogenic 17beta-hydroxysteroid
dehydrogenases. Distinct proﬁles predict the essential thrombo-
cythemic phenotype. Thromb Haemost 2005; 94: 412–421.
27 Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliaﬁco E
et al. Gene expression proﬁling of normal and malignant CD34-
derived megakaryocytic cells. Blood 2004; 104: 3126–3135.
28 D’Andrea AD, Yoshimura A, Youssouﬁan H, Zon LI, Koo JW,
Lodish HF. The cytoplasmic region of the erythropoietin receptor
contains nonoverlapping positive and negative growth-regulatory
domains. Mol Cell Biol 1991; 11: 1980–1987.
29 Stegelmann F, Bullinger L, Griesshammer M, Holzmann K,
Habdank M, Kuhn S et al. High-resolution single-nucleotide
polymorphism array-proﬁling in myeloproliferative neoplasms
identiﬁes novel genomic aberrations. Haematologica 2010; 95:
666–669.
30 Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J,
Rey J et al. Mutations of ASXL1 gene in myeloproliferative
neoplasms. Leukemia 2009; 23: 2183–2186.
31 Forsberg EC, Passegue E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM
et al. Molecular signatures of quiescent, mobilized and leukemia-
initiating hematopoietic stem cells. PLoS One 2010; 5: e8785.
32 James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.
A JAK2 mutation in myeloproliferative disorders: pathogenesis and
therapeutic and scientiﬁc prospects. Trends Mol Med 2005; 11:
546–554.
33 Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors
homozygous for the V617F mutation occur in most patients with
polycythemia vera, but not essential thrombocythemia. Blood
2006; 108: 2435–2437.
34 Tefferi A. Novel mutations and their functional and clinical
relevance in myeloproliferative neoplasms: JAK2, MPL, TET2,
ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128–1138.
35 Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M.
Requirement for p38alpha in erythropoietin expression: a role for
stress kinases in erythropoiesis. Cell 2000; 102: 221–231.
36 Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J
et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines
the MPD phenotypes in transgenic mice. Blood 2008; 111:
3931–3940.
37 Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT
signalling pathway. Semin Cell Dev Biol 2008; 19: 414–422.
38 Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E. Constitutive
Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid
leukemia cells caused by the autocrine secretion of interleukin-6.
Blood 2000; 95: 3765–3770.
39 Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC,
Vainchenker W et al. The myeloproliferative disorder-associated
JAK2 V617F mutant escapes negative regulation by suppressor of
cytokine signaling 3. Blood 2007; 109: 4924–4929.
40 Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of
chromosome 9p is a frequent stem cell defect in polycythemia
vera. Exp Hematol 2002; 30: 229–236.
41 Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP
et al. Comparison of molecular markers in a cohort of patients
with chronic myeloproliferative disorders. Blood 2003; 102:
1869–1871.
42 Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V,
Adelaide J et al. Alterations of NFIA in chronic malignant myeloid
diseases. Leukemia 2009; 23: 583–585.
43 Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early
human erythroid and megakaryocytic cell fate. Cell Stem Cell
2008; 2: 264–273.
44 Iida S, Seto M, Yamamoto K, Komatsu H, Tojo A, Asano S et al.
MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a
serine/proline rich protein homologous to MLLT1 on 19p13.
Oncogene 1993; 8: 3085–3092.
45 Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1
mediates methylation on histone H3 lysine 27 and complements
EZH2 in maintaining stem cell identity and executing pluripo-
tency. Mol Cell 2008; 32: 491–502.
46 Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green
AR et al. JAK2 phosphorylates histone H3Y41 and excludes
HP1alpha from chromatin. Nature 2009; 461: 819–822.
47 Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval
JL et al. JAK2 stimulates homologous recombination and genetic
instability: potential implication in the heterogeneity of myelo-
proliferative disorders. Blood 2008; 112: 1402–1412.
48 Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB,
Lasho T et al. Prevalence and prognostic impact of allelic
imbalances associated with leukemic transformation of Philadel-
phia chromosome-negative myeloproliferative neoplasms. Blood
2010; 115: 2882–2890.
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on Blood Cancer Journal website (http://www.nature.com/bcj)
Identiﬁcation of novel lesions and pathways in MPN
KL Rice et al
11
Blood Cancer Journal